Target and Biomarker Discovery Understanding complex diseases such as cancer require a global view of the genomic changes implicated in its progression. By applying Affymetrix’ whole genome products for gene expression, SNP genotyping and copy number analysis, researchers are elucidating the mechanisms and pathways involved in cancer. This research ultimately uncovers new targets for drug development and disease biomarkers for diagnostic applications.
Today, new tools are providing even more granular views of the cancer genome, including alternative splicing events and transcriptional regulation. Furthermore, a growing number of publications demonstrate the value of combining multiple modes of genomic analysis including gene- and exon- level expression, DNA variation, and copy number data to fundamentally improve our understanding of the disease. Affymetrix provides the most comprehensive platform to combine all such genomic analysis.
Point Mutations 
